Clinicopathological features, treatment outcomes, and prognostic factors of angiosarcoma: a 21-year experience at one center.

Orphanet J Rare Dis · 2025 · PMC12153173 · PMID 40500777

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

A 2021 Asian Sarcoma Consortium study (276 patients) showed a trend toward greater paclitaxel use and slightly better PFS (4.5 vs. 2.8 months) and OS (11.9 vs. 10.6 months) compared to liposomal doxorubicin, but no statistical significance [ 33 ].

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.